- Home
- GBX vs CGON Comparison
GBX vs CGON Comparison
Compare GBX & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBX
- CGON
- Stock Information
- Founded
- GBX 1974
- CGON 2010
- Country
- GBX United States
- CGON United States
- Employees
- GBX N/A
- CGON N/A
- Industry
- GBX Railroads
- CGON
- Sector
- GBX Industrials
- CGON
- Exchange
- GBX Nasdaq
- CGON NYSE
- Market Cap
- GBX 1.8B
- CGON 2.0B
- IPO Year
- GBX N/A
- CGON 2024
- Fundamental
- Price
- GBX $54.33
- CGON $25.95
- Analyst Decision
- GBX Hold
- CGON Strong Buy
- Analyst Count
- GBX 3
- CGON 10
- Target Price
- GBX $64.00
- CGON $65.11
- AVG Volume (30 Days)
- GBX 440.0K
- CGON 574.7K
- Earning Date
- GBX 04-04-2025
- CGON 03-18-2025
- Dividend Yield
- GBX 2.20%
- CGON N/A
- EPS Growth
- GBX 73.07
- CGON N/A
- EPS
- GBX 5.73
- CGON N/A
- Revenue
- GBX $3,611,800,000.00
- CGON $684,000.00
- Revenue This Year
- GBX $2.49
- CGON $158.34
- Revenue Next Year
- GBX $2.20
- CGON N/A
- P/E Ratio
- GBX $9.54
- CGON N/A
- Revenue Growth
- GBX N/A
- CGON 258.12
- 52 Week Low
- GBX $41.40
- CGON $23.91
- 52 Week High
- GBX $71.06
- CGON $46.99
- Technical
- Relative Strength Index (RSI)
- GBX 36.20
- CGON 42.65
- Support Level
- GBX $53.87
- CGON $25.48
- Resistance Level
- GBX $56.10
- CGON $27.05
- Average True Range (ATR)
- GBX 1.65
- CGON 1.55
- MACD
- GBX 0.21
- CGON 0.15
- Stochastic Oscillator
- GBX 36.03
- CGON 48.98
About GBX Greenbrier Companies Inc. (The)
Greenbrier Companies Inc designs, manufactures, and markets railroad freight car equipment in North America and Europe, marine barges in North America and provides wheel services, railcar refurbishment, and parts, leasing and other services to the railroad. Its segments include Manufacturing, Maintenance Services and Leasing & Management Services. The company generates a majority of its revenue from the manufacturing segment. Geographically, it derives a majority of revenue from the United States.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.